Profile
International Journal of Clinical Research & Trials Volume 3 (2018), Article ID 3:IJCRT, 07 pages
https://doi.org/10.15344/2456-8007/2018/124
Research Article
Current Efficacy of the First Line Uncomplicated Malaria Treatment in Two Sentinels Sites of Côte d’Ivoire

Offianan Andre Toure*1, N’Guessan Tiacoh Landry1, Ira Bonouman Ama Valerie1, Assi Serge Brice2, Kouame Emmanuel1, Kokora Adonis1, Yao Serge Stephane1, Amata Eric3, Kinifo-Lawson Viviane4, Adji Eric Gbessi1, Beourou Sylvain1, Tuo Karil1, Ako Ako Aristide Berenger1, Gnondjui Albert1, Djaman Joseph5,6 and Jambou Ronan1,7

1Unité de Paludologie, Institut Pasteur Côte d’Ivoire, Côte d’Ivoire
2Institut Pierre Richet Bouake/Programme National de Lutte contre le Paludisme, Abidjan Côte d’Ivoire, Côte d’Ivoire
3Formation Sanitaire Urbaine à Base Communautaire d’Anonkoua-Kouté Abidjan, Côte d’Ivoire
4Centre de Santé Urbain de Libreville, Man, Côte d’Ivoire
5Département de Biochimie Clinique et Fondamentale, Institut Pasteur Côte d’Ivoire
6Laboratoire de Pharmacodynamie-Biochimique UFR Biosciences, Université Félix Houphouët-Boigny Abidjan, Côte d’Ivoire
7Département de Parasitologie et Insectes vecteurs, Institut Pasteur Paris France, France
Dr. Offianan Andre Toure, Unité de Paludologie, Institut Pasteur Côte d’Ivoire, Côte d’Ivoire; E-mail: andre_offianan@yahoo.fr
19 October 2017; 01 March 2018; 03 March 2018
Toure OA, Landry NT, Valerie IBA, Brice AS, Emmanuel K, et al. (2018) Current Efficacy of the First Line Uncomplicated Malaria Treatment in Two Sentinels Sites of Côte d’Ivoire. Int J Clin Res Trials 3: 124. doi: https://doi.org/10.15344/2456-8007/2018/124
The National Malaria Control Program of Côte d’Ivoire and WHO Global Fund sponsored this trial.

Abstract

Background: Artemisinin combination therapies have been wildly used in the treatment of uncomplicated falciparum malaria in most endemic countries. This strategy has been implemented in Côte d’Ivoire since 2005 with Artesunate + Amodiaquine (AS + AQ) and Artemether + lumefantrine (AL). The goal of this study was to assess efficacy and safety of these two drugs in two sentinel’s sites, Man and Abidjan in Côte d’Ivoire.
Methods: An open label, randomized, clinical trial was conducted in Man in the west and Abidjan in the south of Côte d’Ivoire. Patients older than 6 months with uncomplicated falciparum malaria after consent were randomized in AS+AQ and AL group and were followed up for 42 days.
The first endpoint was Adequate Clinical and Parasitological Response adjusted by PCR at day 42. The second endpoints were fever and parasite clearance time, crude cure rate at day 42 and safety of the two ACTs.
Results: A total of 241 patients were randomized in AS+AQ (120) and AL (121) group. The crude cure rate at day 42 in PP analysis was 95.8% and 87.9% in AS+AQ and AL respectively. After correction by PCR ACPR at day 42 was 99.2% in AS+AQ group and 97.4% in AL group. The two ACTs were well tolerated.
Conclusion: AS+AQ and AL remains efficacious in the uncomplicated malaria treatment in the two areas but continue monitoring is needed particularly for AL.